CRL · Charles River Laboratories International
242 filings
CRL 8-K Current Reports
Charles River Laboratories International - 242 current reports
CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 8, 2016
- 8-K · Jan 19, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 12, 2016
- 8-K · Mar 10, 2016
- 8-K · Apr 5, 2016
- 8-K · May 4, 2016
- 10-Q · May 4, 2016
- 8-K · May 16, 2016
- 8-K/A · May 16, 2016
- 8-K/A · Jun 15, 2016
- 10-Q · Aug 3, 2016
- 8-K · Aug 3, 2016
- 8-K · Nov 2, 2016
- 10-Q · Nov 2, 2016
- 8-K · Nov 2, 2016
- 8-K · Jan 10, 2017
- 10-K · Feb 14, 2017
- 8-K · Feb 14, 2017
- 8-K · Apr 26, 2017
- 8-K · May 10, 2017
- 10-Q · May 10, 2017
- 8-K · May 11, 2017
- 8-K · Jul 6, 2017
- 10-Q · Aug 9, 2017
- 8-K · Aug 9, 2017
- 8-K · Nov 9, 2017
- 10-Q · Nov 9, 2017
- 8-K · Nov 24, 2017
- 8-K · Jan 9, 2018
- 8-K · Jan 16, 2018
- 8-K · Feb 13, 2018
- 10-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Feb 13, 2018
- 8-K · Mar 26, 2018
- 8-K · Apr 3, 2018
- 8-K · May 10, 2018
- 10-Q · May 10, 2018
- 8-K · May 14, 2018
- 8-K · Jun 14, 2018
- 8-K/A · Jun 14, 2018
- 10-Q · Aug 8, 2018
- 8-K · Aug 8, 2018
- 8-K · Aug 8, 2018
- 8-K · Aug 31, 2018
- 8-K · Oct 3, 2018
- 10-Q · Nov 7, 2018
- 8-K · Nov 7, 2018
- 10-K · Feb 13, 2019
- 8-K · Feb 13, 2019
- 8-K · Feb 15, 2019
- 8-K · Apr 30, 2019
- 8-K · May 1, 2019
- 10-Q · May 7, 2019
- 8-K · May 7, 2019
- 8-K · May 22, 2019
- 8-K · Jul 31, 2019
- 10-Q · Jul 31, 2019
- 8-K · Aug 2, 2019
- 8-K · Oct 1, 2019
- 8-K · Oct 21, 2019
- 8-K · Oct 23, 2019
- 10-Q · Nov 6, 2019
- 8-K · Nov 6, 2019
- 8-K · Feb 11, 2020
- 10-K · Feb 11, 2020
- 8-K · Mar 4, 2020
- 10-Q · May 7, 2020
- 8-K · May 7, 2020
- 8-K · May 8, 2020
- 8-K · Aug 5, 2020
- 10-Q · Aug 5, 2020
- 8-K · Oct 19, 2020
- 8-K · Oct 29, 2020
- 10-Q · Oct 29, 2020
- 10-K · Feb 17, 2021
- 8-K · Feb 17, 2021
- 8-K · Feb 17, 2021
- 8-K · Mar 9, 2021
- 8-K · Mar 23, 2021
- 8-K · Mar 29, 2021
- 8-K · Apr 23, 2021
- 10-Q · May 4, 2021
- 8-K · May 4, 2021
- 8-K · May 10, 2021
- 8-K · May 18, 2021
- 10-Q · Aug 4, 2021
- 8-K · Aug 4, 2021
- 10-Q · Nov 3, 2021
- 8-K · Nov 3, 2021
- 8-K · Nov 9, 2021
- 8-K · Nov 12, 2021
- 8-K · Dec 15, 2021
- 8-K · Dec 27, 2021
- 8-K · Jan 11, 2022
- 10-K · Feb 16, 2022
- 8-K · Feb 16, 2022
- 8-K · Mar 28, 2022
- 10-Q · May 4, 2022
- 8-K · May 4, 2022
- 8-K · May 12, 2022
- 8-K · Jun 8, 2022
- 8-K · Aug 3, 2022
- 10-Q · Aug 3, 2022
- 10-Q · Nov 2, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 30, 2022
- 8-K · Dec 6, 2022
- 10-K · Feb 22, 2023
- 8-K · Feb 22, 2023
- 8-K · May 11, 2023
- 10-Q · May 11, 2023
- 8-K · May 15, 2023
- 10-Q · Aug 9, 2023
- 8-K · Aug 9, 2023
- 10-Q · Nov 8, 2023
- 8-K · Nov 8, 2023
- 8-K · Nov 15, 2023
- 8-K · Jan 16, 2024
- 8-K · Jan 24, 2024
- 10-K · Feb 14, 2024
- 8-K · Feb 14, 2024
- 10-Q · May 9, 2024
- 8-K · May 9, 2024
- 8-K · May 10, 2024
- 8-K · Aug 7, 2024
- 10-Q · Aug 7, 2024
- 8-K · Nov 6, 2024
- 10-Q · Nov 6, 2024
- 8-K · Dec 13, 2024
- 8-K · Jan 14, 2025
- 10-K · Feb 19, 2025
- 8-K · Feb 19, 2025
- 8-K · Feb 21, 2025
- 8-K · May 7, 2025
- 10-Q · May 7, 2025
- 8-K · May 7, 2025
- 8-K · May 23, 2025
- 10-Q · Aug 6, 2025
- 8-K · Aug 6, 2025
- 8-K · Sep 16, 2025
- 8-K/A · Sep 19, 2025
- 8-K · Nov 5, 2025
- 10-Q · Nov 5, 2025
- 8-K · Nov 17, 2025
- 8-K · Dec 3, 2025
- 8-K · Jan 9, 2026
- 8-K · Jan 13, 2026
- 10-K · Feb 18, 2026
- 8-K · Feb 18, 2026
- 8-K · Feb 18, 2026
- 8-K · Feb 25, 2026
- 10-Q · May 7, 2026
- 8-K · May 7, 2026
- 8-K · May 11, 2026
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026
- 8-K · Sep 24, 2026
- 10-Q · Nov 4, 2026
- 8-K · Nov 4, 2026
- 8-K · Nov 9, 2026
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Nov 9, 2026)
Charles River Laboratories International (CRL) has announced a definitive agreement to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately $470 million in cash, plus potential performance-based payments up to $75 million. This strategic acquisition is expected to close in the first half of 2027, subject to customary approvals. The transaction is designed to significantly strengthen CRL's bioanalysis capabilities, particularly in the high-growth clinical bioanalysis sector, and enhance its offering across the entire drug development lifecycle. This move aligns with CRL's "Pathway to Purpose" strategy, aiming to bolster scientific leadership, expand its presence in complex modalities, and improve client continuity from preclinical to clinical testing. The acquired operations include two sites in Exton, PA, approximately 150,000 square feet, and employ around 340 people. Frontage's bioanalysis and DMPK businesses represented about 40% of their total 2025 revenue. CRL anticipates the acquired businesses will grow in line with the projected bioanalysis sector growth. While expected to be neutral to non-GAAP EPS in 2027, the acquisition is projected to be accretive thereafter, with financing to be drawn from the company's credit facility and available cash.
Charles River Laboratories International 8-K Report, Financial Results (Nov 4, 2026)
Charles River Laboratories International, Inc. (NYSE: CRL) reported third-quarter 2026 results for the quarter ended September 26, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K. Third-quarter revenue was $982.7 million, down from $1,004.9 million a year earlier, mainly due to the May 2026 divestitures; on an organic basis revenue rose 4.7%. GAAP earnings per diluted share were $6.86, boosted by a $245.6 million, or $5.06 per share, benefit from the reversal of acquired tax reserves. Non-GAAP diluted EPS was $3.09, up 27.2% from $2.43. The company raised its 2026 guidance. Organic revenue growth is now expected to be at least +1.5% (previously 0.0% to 1.0%), and non-GAAP EPS is now $11.35 to $11.55 (previously $11.15 to $11.45). GAAP EPS guidance rose to $8.15 to $8.35 from $3.05 to $3.35. Management attributed the increase mainly to better-than-expected DSA segment performance and a lower tax rate. Management also highlighted the 2026 Investor Day unveiling of its Pathway to Purpose strategy and Create the Future initiative. Segment results were mixed. DSA revenue was $596.3 million, with organic growth of 5.9% and non-GAAP operating margin of 26.8%. Manufacturing Solutions revenue was $178.9 million, with organic growth of 7.4% and non-GAAP operating margin of 38.6%. Research Models and Services revenue was $207.5 million, with organic revenue down 0.6% and non-GAAP operating margin of 24.4%.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Sep 24, 2026)
Charles River Laboratories International, Inc. (NYSE: CRL) furnished a press release dated September 24, 2026, issued in connection with its 2026 Investor Day. The release outlines the company's "Pathway to Purpose" strategy, which rests on three initiatives: modernizing the company to drive productivity and efficiency, strengthening its scientific portfolio, and delivering a customized, client-centric approach. The company expects over $300 million in cumulative savings from its Create the Future™ program from 2027 through 2030, and it expects bioanalysis revenue to grow organically at a high-single-digit CAGR to approximately $450 million in 2030. The company reaffirmed its 2026 financial guidance, last updated on August 5, 2026, and now expects revenue and non-GAAP earnings per share at the upper ends of their prior ranges, primarily reflecting continued favorable demand from biopharmaceutical clients. The 2026 guidance ranges are 0% to 1% organic revenue growth, a non-GAAP operating margin of 21.0% to 21.3%, and non-GAAP EPS of $11.15 to $11.45. For 2030, the company introduced long-term targets of 5% to 7% organic revenue growth (2027-2030 CAGR), a non-GAAP operating margin of approximately 24%, and low-double-digit non-GAAP EPS growth (2027-2030 CAGR). The company states these targets do not include future acquisitions or divestitures, are not projections, and are not financial guidance. The information is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
Charles River Laboratories International 8-K Report, Financial Results (Aug 5, 2026)
Charles River Laboratories International, Inc. reported second-quarter 2026 results for the quarter ended June 27, 2026, with revenue of $1.00 billion, down 2.7% from $1.03 billion a year earlier, and organic revenue growth of 0.1%. GAAP results were weaker, with a net loss attributable to common shareholders of $(1.5) million, or $(0.03) per diluted share, compared with net income of $52.3 million, or $1.06 per share, a year earlier. The company attributed the decline mainly to a $63.7 million, or $1.40 per share, loss on the CDMO and Cell Solutions divestiture. On a non-GAAP basis, diluted EPS was $3.02, versus $3.12 in the prior-year quarter, and the non-GAAP operating margin fell to 20.5% from 22.1%, mainly on higher study-related direct costs in the DSA segment. Management cited improving demand, particularly in the DSA segment, where it recorded the highest net book-to-bill in nearly four years. Based on second-quarter performance and improving demand trends, the company raised its 2026 guidance: organic revenue growth is now 0.0% to 1.0% (previously (1.5)% to (0.5)%), and non-GAAP EPS is now $11.15 to $11.45 (previously $10.80 to $11.30). GAAP EPS guidance was lowered to $3.05 to $3.35 from $5.35 to $5.85, primarily because of the divestiture-related net loss. The company also repurchased $100.0 million of stock in the quarter and has $700.0 million remaining under its $1.0 billion authorization. An Investor Day is scheduled for September 24, 2026.
Charles River Laboratories International 8-K Report, Executive Changes (May 11, 2026)
Charles River Laboratories International, Inc. filed this Form 8-K dated May 11, 2026 to report the results of its 2026 annual meeting of shareholders, held May 5, 2026. At the meeting, shareholders approved the company's 2026 Long-Term Incentive Plan, which the Board had adopted on March 11, 2026, subject to shareholder approval. The filing states that the full description of the plan appears in the Proxy Statement filed March 31, 2026, and that the plan itself is attached as Exhibit 10.1. All twelve director nominees were elected to serve until the 2027 annual meeting. Shareholders also approved, on an advisory basis, the compensation of the named executive officers, approved the 2026 Long-Term Incentive Plan, and ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2026. The vote on the auditor ratification was the one proposal where the filing reports zero broker non-votes, and the filing identifies Computershare Trust Company, N.A. as the independent proxy tabulator and inspector of election. For investors, the filing's key takeaways are the shareholder approval of the new incentive plan and the continued election of the full board slate. Vote counts for Abraham Ceesay (35,798,426 for and 8,288,770 against) were noticeably lower in support than those of the other directors, and the filing reports them without further commentary.
Charles River Laboratories International 8-K Report, Financial Results (May 7, 2026)
Charles River Laboratories International, Inc. (NYSE: CRL) reported first-quarter 2026 results on May 7, 2026. Total revenue was $995.8 million, up 1.2% from $984.2 million a year earlier, though organic revenue declined 1.5% after adjusting for a 2.8% foreign currency benefit and a 0.1% divestiture reduction. GAAP results were weak: the company posted a net loss attributable to common shareholders of $(14.8) million, or $(0.30) per diluted share, versus net income of $25.5 million, or $0.50 per share, a year earlier. The decline was principally due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture, or $1.53 per share. Non-GAAP diluted EPS was $2.06, down 12.0% from $2.34, and non-GAAP operating margin fell to 16.3% from 19.1%. By segment, Research Models and Services (RMS) revenue declined 2.2% reported and 5.5% organically, and Discovery and Safety Assessment (DSA) revenue rose 0.7% reported but fell 1.4% organically. Manufacturing Solutions grew 6.8% reported and 2.9% organically, supported by Microbial Solutions. The company completed the divestiture of its CDMO and Cell Solutions businesses to GI Partners on May 6, 2026, and expects to sell certain European Discovery Services sites in May 2026. It repurchased 1.1 million shares for $200.0 million in the quarter and had $800.0 million remaining under its $1.0 billion authorization. CRL reaffirmed its 2026 organic revenue growth guidance of (1.5)% to (0.5)% and non-GAAP EPS guidance of $10.80 to $11.30. It lowered its reported revenue growth outlook to (5.5)% to (4.0)% from (5.0)% to (3.5)%, reflecting foreign exchange assumptions, and set GAAP EPS guidance at $5.35 to $5.85.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Feb 25, 2026)
On February 25, 2026, Charles River Laboratories International, Inc. announced two planned divestitures. It signed a definitive agreement to sell its contract development and manufacturing (CDMO) and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments. The businesses generated combined 2025 annual revenue of $143 million, including $117 million in the Manufacturing Solutions segment and $26 million in the Research Models and Services segment. The sale covers CDMO sites in Tennessee, Maryland, and the United Kingdom and a Cell Solutions site in California. Separately, the company signed a definitive agreement to sell certain European Discovery Services assets to IQVIA Holdings Inc. for approximately $145 million in cash, subject to customary closing adjustments, plus potential additional payments of up to $10 million. The assets represent $144 million of 2025 annual revenue in the Discovery and Safety Assessment segment. The company will retain other drug discovery capabilities totaling approximately 40% of its 2025 Discovery Services revenue. Both transactions are expected to close in the second quarter of 2026, subject to customary closing conditions. The company updated its 2026 guidance, first provided on February 18, 2026, to reflect the divestitures. The divestitures are expected to reduce reported revenue by slightly more than $200 million in 2026 and reduce organic revenue growth guidance by more than 50 basis points. Reported revenue growth/(decrease) is now guided to (5.0)% to (3.5)%, and organic revenue growth/(decrease) to (1.5)% to (0.5)%. Non-GAAP earnings per share guidance rises to $10.80 to $11.30 from $10.70 to $11.20, reflecting approximately $0.10 of partial-year accretion. The transactions are expected to add at least 100 basis points of non-GAAP operating margin improvement in 2026.
Charles River Laboratories International 8-K Report, Executive Changes (Feb 18, 2026)
Charles River Laboratories International, Inc. announced on February 18, 2026 that it has appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, with a tentative start date of April 6, 2026. Mr. Coleman, 58, most recently served since 2024 as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., described in the filing as a $1-billion healthcare services business. His earlier roles include CFO of DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation, where he also served as Executive Vice President and Chief Operating Officer from 2019 to 2022. He succeeds Michael G. Knell, who has served as interim CFO since September 2025 and will remain Corporate Senior Vice President and Chief Accounting Officer. The filing describes an at-will employment offer letter dated February 12, 2026, with the following material terms: a base salary of $800,000 annually, a 2026 target bonus of 85% of base salary (pro-rated to his hire date), a 2026 equity award with a grant value of $3,000,000 (60% performance share units and 40% restricted stock units) beginning in May 2026, a one-time new hire cash award of $1,875,000, and a one-time new hire restricted stock unit award with a grant value of $3,500,000 vesting 25% annually over four years. The full offer letter is filed as Exhibit 10.1. The filing states there are no family relationships between Mr. Coleman and any director or executive officer, and no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Charles River Laboratories International 8-K Report, Financial Results (Feb 18, 2026)
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter and full-year 2025 results on February 18, 2026, under Item 2.02 of this Form 8-K. Fourth-quarter revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million a year earlier; on an organic basis, revenue declined 2.6%. The GAAP net loss available to common shareholders was $(276.6) million, or $(5.62) per diluted share, driven by non-cash intangible asset impairments of $211.0 million and a goodwill impairment of $165.0 million in the Biologics Solutions reporting unit. Non-GAAP diluted earnings per share were $2.39, down 10.2% from $2.66. For full-year 2025, revenue was $4.02 billion, down 0.9%, with GAAP diluted loss per share of $(2.91) and non-GAAP diluted EPS of $10.28, down 0.4%. Segment performance was mixed. Fourth-quarter DSA net bookings improved substantially, which management cites as evidence of stabilizing biopharmaceutical demand, though DSA revenue fell 2.0% and its non-GAAP operating margin declined to 20.1% from 24.7%. RMS revenue rose 1.0%, while Manufacturing Solutions revenue rose 0.7% on a reported basis but fell 2.1% organically. For 2026, the company guides to reported revenue growth of at least flat to +1.5%, organic revenue growth of (1.0)% to at least flat, GAAP EPS of $6.30 to $6.80, and non-GAAP EPS of $10.70 to $11.20. The guidance excludes planned divestitures representing approximately 7% of annual revenue for 2025 and estimated 2026, and management expects a return to organic revenue growth in the second half of 2026.
Charles River Laboratories International 8-K Report, Financial Results (Jan 13, 2026)
Charles River Laboratories International, Inc. ("Charles River") filed this Form 8-K on January 13, 2026 to furnish materials for its presentation at the J.P. Morgan 44th Annual Healthcare Conference. The company stated that demand trends for its Discovery and Safety Assessment (DSA) business continued to improve throughout the second half of 2025, with a preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter of 2025. Improvement was primarily driven by small and mid-sized biotech clients, and global biopharma net bookings also increased in the fourth quarter of 2025. The company noted that these preliminary figures remain subject to completion of its audited 2025 results. For 2026, Charles River expects the top end of its organic revenue growth guidance ranges to be at least flat for both the consolidated outlook and the DSA segment. The company is cautiously optimistic that favorable DSA demand indicators will continue into 2026, resulting in a return to revenue growth in the second half of 2026. Expected improvement in Manufacturing organic revenue growth is anticipated to be offset by RMS headwinds from the timing of non-human primate (NHP) shipments and CRADL occupancy. Foreign exchange is expected to be an incremental benefit of 100-150 bps to reported revenue growth. The company also expects more than $100 million in incremental 2026 cost savings to offset annual cost inflation until revenue growth reinvigorates. Charles River also disclosed two acquisitions. It has signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a provider of non-human primates, for an expected total purchase price of approximately $510 million, closing early in the first quarter of 2026 and expected to be accretive to non-GAAP EPS by approximately $0.25 in 2026 and $0.60 in 2027. It has also exercised its option to acquire the remaining 79% stake in PathoQuest SAS for approximately €51.6 million (about $60 million), expected to close by the end of the first quarter of 2026. PathoQuest is expected to generate annual revenue of approximately $15 to $20 million in 2026 and is not expected to have a material impact on 2026 or 2027 GAAP or non-GAAP results. The 2026 outlook does not yet reflect these acquisitions or planned divestitures.
Charles River Laboratories International 8-K Report, Executive Changes (Jan 9, 2026)
Charles River Laboratories International, Inc. announced a CEO leadership transition on January 8, 2026. James C. Foster, currently Chairman, President and Chief Executive Officer, intends to step down as CEO and Chairman of the Board, and Birgit Girshick, the Company's Chief Operating Officer, will become CEO, both effective May 5, 2026 (the "Transition Date"). Foster is expected to remain a non-executive director afterward, and Dr. Martin Mackay, the current Lead Independent Director, is expected to become Chair of the Board on the Transition Date. Girshick has also been nominated to join the Board at the 2026 Annual Meeting of Shareholders, expected on the Transition Date, and the Board approved increasing its size from 11 to 12 seats effective then. Elliott Investment Management L.P. and related Elliott entities provided limited consents under their May 6, 2025 Cooperation Agreement with the Company to permit this addition. Compensation terms for Girshick include a base salary increase to $1,200,000 effective February 1, 2026, a target annual cash incentive of 100% of base salary effective May 1, 2026, and an initial equity grant with a target fair market value of $9,000,000 (80% performance share units, 20% restricted stock units) expected in May 2026. Her change-in-control agreement is to be amended before the Transition Date, providing a lump sum severance of three times base salary plus target bonus, three years of benefits continuation, and outplacement services upon a qualifying termination within the first year after a change in control. Foster received a grant of restricted stock units with an underlying fair market value of $3,000,000, expected on March 2, 2026, with two-year cliff vesting.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Dec 3, 2025)
Charles River Laboratories International, Inc. ("Charles River") filed this Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) to announce that management will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025, at approximately 10:00 a.m. Eastern time. The filing states that management intends to address certain fourth-quarter demand trends, specifically trends in Discovery and Safety Assessment (DSA) booking activity and related key performance indicators. The key disclosed update is that DSA net book-to-bill has continued to improve each month since the beginning of the third fiscal quarter of 2025. The Company also notes that seasonality during the fourth-quarter holiday period and early January may affect near-term proposal and booking activity, and says it is encouraged by the positive momentum and upward trends since the middle of fiscal 2025. The filing does not provide specific net book-to-bill values, revenue, or earnings figures. The information is furnished rather than filed, so it is not incorporated into Securities Act or Exchange Act filings unless expressly referenced. The filing includes forward-looking statement cautions covering DSA demand, proposal and booking trends, and refers readers to the risk factors in the Company's 2024 Form 10-K and its Form 10-Q for the quarter ended September 27, 2025. The Company disclaims any duty to update these statements except as required by law.
Charles River Laboratories International 8-K Report, Corporate Update (Nov 17, 2025)
Charles River Laboratories International, Inc. (Company) disclosed in a Current Report on Form 8-K under Item 8.01 (Other Events) that the U.S. Securities and Exchange Commission's Division of Enforcement notified the Company on November 14, 2025 that it had concluded its investigation. Based on the information available to the Division, it does not intend to recommend an enforcement action by the SEC against the Company. The SEC inquiry began with a request received on May 16, 2023 for the Company to voluntarily provide information. It was later augmented with a document subpoena and additional inquiries, and related primarily to the sourcing of non-human primates and related disclosures. The Audit Committee had also retained counsel to conduct an independent investigation into certain issues raised in the SEC investigation. The Company stated that its independent investigation has also concluded, with no material findings. For investors, the filing indicates that the matter has been closed without an SEC enforcement recommendation and that the internal review identified no material findings.
Charles River Laboratories International 8-K Report, Financial Results (Nov 5, 2025)
Charles River Laboratories International, Inc. reported third-quarter 2025 results for the quarter ended September 27, 2025, in a press release furnished under Item 2.02 as Exhibit 99.1. Revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion a year earlier. Excluding a 1.3% favorable foreign currency impact and a 0.2% reduction from a divestiture, organic revenue declined 1.6%. GAAP earnings per diluted share were $1.10, compared with $1.33 in the prior-year quarter, primarily due to a $0.33 per share loss from venture capital and other strategic investments. Non-GAAP diluted EPS was $2.43, down 6.2% from $2.59. GAAP operating margin rose to 13.3% from 11.6%, driven by lower restructuring costs, while non-GAAP operating margin eased to 19.7% from 19.9%. By segment, Research Models and Services (RMS) grew revenue 7.9% to $213.5 million, with organic growth of 6.5% driven mainly by large research model products. Discovery and Safety Assessment (DSA) revenue fell 2.3% to $600.7 million, with organic decline of 3.1% on lower discovery and regulated safety assessment volume. Manufacturing Solutions revenue fell 3.1% to $190.7 million, with organic decline of 5.1% led by CDMO and Biologics Testing, partly offset by Microbial Solutions. For 2025, the company narrowed its revenue and non-GAAP EPS guidance to the middle and upper ends of prior ranges, respectively. Reported revenue growth is now guided at (1.5)% to (0.5)%, and non-GAAP EPS at $10.10 to $10.30, versus the prior $9.90 to $10.30. GAAP EPS guidance is $4.15 to $4.35, down from $4.25 to $4.65 previously. Management stated that demand remains stable and some signals suggest the industry may be recovering, but sustained improvement will take time and the company remains cautious.
Charles River Laboratories International 8-K/A Report, Executive Changes (Sep 19, 2025)
Charles River Laboratories International, Inc. filed this Form 8-K/A on September 19, 2025, to amend its Form 8-K filed on September 16, 2025. The original report disclosed the resignation of Flavia H. Pease as Corporate Executive Vice President and Chief Financial Officer, and the appointment of Michael G. Knell as interim Chief Financial Officer. This amendment supplies compensation details for Mr. Knell that had not been determined when the original report was filed. The Compensation Committee of the Company's Board of Directors approved the compensation changes on September 15, 2025, in connection with Mr. Knell's appointment as interim Chief Financial Officer and interim principal financial officer. The package includes an increase in annual base salary to $500,000, effective September 28, 2025; a $10,000 monthly cash payment during his term as interim Chief Financial Officer, effective October 1, 2025; and a one-time grant of restricted stock units with a grant value of $500,000. The restricted stock units are to be granted on November 6, 2025, the first business day after the press release on third-quarter 2025 financial results. Half vest on the first anniversary of the grant date and half on the second anniversary. The filing is signed by Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.
Charles River Laboratories International 8-K Report, Executive Changes (Sep 16, 2025)
Charles River Laboratories International, Inc. (NYSE: CRL) disclosed that Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer, informed the company on September 12, 2025 of her intention to resign, effective September 29, 2025. The filing states the resignation is not the result of any disagreement with the company on financial statements, internal control over financial reporting, operations, policies or practices. The press release attached as Exhibit 99.1 says she is leaving to pursue another opportunity. The Board has appointed Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, as interim Chief Financial Officer effective upon Ms. Pease's departure, until a permanent successor is named. Mr. Knell, age 49, joined the company in April 2017 and previously served as Chief Accounting Officer and Vice President of Finance at Bruker Corporation from 2012 to 2017. The company has commenced a comprehensive search for a permanent CFO. Information regarding Item 5.02(c)(3) compensation arrangements for Mr. Knell has not yet been determined as of the report date. In the same press release, the company reaffirmed its 2025 revenue and non-GAAP earnings per share guidance, previously provided on August 6, 2025, which it states is supported by its current outlook for third-quarter performance. Chair, President and CEO James C. Foster credited Ms. Pease with helping navigate a challenging demand environment and leading cost-structure initiatives.
Charles River Laboratories International 8-K Report, Financial Results (Aug 6, 2025)
Charles River Laboratories International, Inc. reported second-quarter 2025 results for the quarter ended June 28, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K dated August 6, 2025. Total revenue was $1,032.1 million, up 0.6% from $1,026.1 million a year earlier, with organic revenue declining 0.5% after a 1.2% foreign currency benefit. GAAP net income available to common shareholders was $52.3 million, or $1.06 per diluted share, versus $1.74 a year earlier, driven mainly by accelerated amortization of certain CDMO client relationships, restructuring costs, and third-party legal and advisory costs. Non-GAAP diluted EPS rose 11.4% to $3.12 from $2.80, and non-GAAP operating margin improved to 22.1% from 21.3%. The Discovery and Safety Assessment (DSA) segment, the largest by revenue at $618.0 million, saw organic revenue decline 2.4%, while Research Models and Services (RMS) grew organically 2.3% and Manufacturing Solutions grew organically 2.9%. Management said biopharmaceutical demand is stabilizing and that DSA results were better than initially expected. The company also reported that the U.S. Department of Justice had closed the grand jury and parallel civil investigations relating to non-human primate shipments from late 2022 and early 2023. The company raised its full-year 2025 guidance. Reported revenue growth is now expected to be (2.5)% to (0.5)%, up from (5.5)% to (3.5)%, and organic revenue growth is now (3.0)% to (1.0)%, up from (4.5)% to (2.5)%. GAAP EPS estimate is $4.25 to $4.65, and non-GAAP EPS estimate is $9.90 to $10.30, up from $9.30 to $9.80.
Charles River Laboratories International 8-K Report, Executive Changes (May 23, 2025)
Charles River Laboratories International, Inc. filed this Current Report on Form 8-K to disclose two matters: an employment agreement amendment for its Chair, President and Chief Executive Officer, and the results of its 2025 Annual Meeting of Shareholders held on May 20, 2025. On May 20, 2025, the Company and James C. Foster entered into Amendment No. 1 to his Amended and Restated Employment Agreement dated May 18, 2021. The amendment extends his employment term by one year, to February 12, 2027, and leaves all other terms unchanged. The Company states that the full amendment will be filed as an exhibit to its Quarterly Report on Form 10-Q for the second quarter of fiscal 2025. At the Annual Meeting, shareholders elected seven directors to serve until the 2026 Annual Meeting. Mr. Foster received 39,676,718 votes for and 1,908,059 against, while the other six nominees each received more than 40 million votes for. Shareholders approved, on an advisory basis, the compensation of the named executive officers, with 40,218,870 votes for, 1,432,240 against and 102,252 abstaining. Shareholders also ratified PricewaterhouseCoopers LLP as independent auditors, with 42,348,057 votes for and 1,551,238 against. A shareholder proposal submitted by PETA to publish a report on non-human primates imported by the Company was not approved, receiving 3,457,547 votes for and 38,051,509 against. Board composition also changed. Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman did not stand for re-election after their terms expired, as previously disclosed in a Form 8-K filed May 7, 2025. On May 20, 2025, the Board appointed Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves to fill the resulting four vacancies, each with a term expiring at the 2026 Annual Meeting.
Charles River Laboratories International 8-K Report, Material Agreement (May 7, 2025)
On May 6, 2025, Charles River Laboratories International, Inc. entered into a Cooperation Agreement with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (the Elliott Parties), effective that date. Under the agreement, the company will appoint Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves to its Board of Directors effective following the 2025 Annual Meeting, each with a term expiring at the 2026 Annual Meeting. Four incumbent directors, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman, will not stand for re-election at the 2025 Annual Meeting, which is scheduled for May 20, 2025. The company also agreed to appoint at least one Investor Designated Director to the Strategic Partnership and Capital Allocation Committee, the Compensation Committee and the Corporate Governance and Nominating Committee, and to limit the Board to no more than 11 members until the Cooperation Period expires. The Board, through the Strategic Committee, will conduct a comprehensive review and evaluation of the company's business and prospects, including an examination of various alternatives to enhance long-term stockholder value. The Cooperation Agreement includes voting commitments, customary standstill restrictions and mutual non-disparagement provisions. The Cooperation Period runs until the later of 30 calendar days before the advance notice deadline for 2026 Annual Meeting nominations and the day an Investor Director ceases to serve on the Board. The company's press release states that Elliott is its largest investor and that the Board will have eleven directors, nine of whom will be independent. The press release also states that Elliott's partner said the company's current value is significantly disconnected from its underlying potential. Items 5.02(d) and 1.01 describe committee assignments and a non-employee director initial equity award valued at $255,500 before pro-rata adjustment, split 50% restricted stock or units and 50% stock options. The filing is signed by Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer.
Charles River Laboratories International 8-K Report, Financial Results (May 7, 2025)
Charles River Laboratories International, Inc. reported first-quarter 2025 results, with total revenue of $984.2 million, down 2.7% from $1,011.6 million in the first quarter of 2024. Organic revenue decreased 1.8%, with declines in all three business segments. GAAP net income available to common shareholders was $25.5 million, or $0.50 per diluted share, compared with $1.30 per diluted share a year earlier. The GAAP decline was driven by lower revenue and accelerated amortization of certain CDMO client relationships, which raised amortization of intangible assets to $65.3 million from $32.6 million. Non-GAAP diluted EPS was $2.34, up 3.1% from $2.27, helped mainly by lower tax rates, interest expense and diluted share count. The company increased its 2025 guidance, now projecting reported revenue decline of (5.5)% to (3.5)% and GAAP EPS of $4.35 to $4.85, versus prior ranges of (7.0)% to (4.5)% and $4.30 to $4.80. Non-GAAP EPS guidance rose to $9.30 to $9.80 from $9.10 to $9.60. Management attributed the raise primarily to improved DSA net bookings in the first quarter, which are expected to add DSA revenue this year, particularly in the first half. CEO James C. Foster described the quarter as showing signs of demand stabilization, with DSA bookings at their highest level in two years, while maintaining a balanced yet cautious outlook. Capital allocation was active: the company repurchased 2.1 million shares for $350.0 million in the quarter and had $549.3 million remaining under its $1.0 billion authorization as of March 29, 2025. Long-term debt, net and finance leases rose to $2.51 billion from $2.24 billion at year-end 2024. The filing also notes ongoing third-party legal costs in the DSA segment tied to U.S. government investigations into the NHP supply chain, which the company excludes from non-GAAP results.
Charles River Laboratories International 8-K Report, Corporate Update (Feb 21, 2025)
Charles River Laboratories International, Inc. (the "Company") disclosed in this Form 8-K, filed February 21, 2025, that Chair, President and CEO James C. Foster and Corporate Executive Vice President and Chief Operating Officer Birgit Girshick each bought shares of Company common stock in open market transactions on February 20, 2025. Mr. Foster purchased 6,075 shares at an average price of $165.01, for an aggregate purchase price of approximately $1 million. Ms. Girshick purchased 1,514 shares at an average price of $164.63, for an aggregate purchase price of approximately $250,000. Both executives said the purchases reflect their confidence in the Company's strategic direction and long-term growth prospects. Before making these purchases, both executives terminated their Rule 10b5-1 trading plans on February 19, 2025, so that the buys would not unintentionally violate Section 16 short-swing profit rules through open market sales within six months of purchases. Mr. Foster's terminated plan, dated February 26, 2024, allowed for the sale of a maximum of 129,721 shares, and he sold 25,000 shares under it on August 1, 2024. Ms. Girshick's terminated plan, dated November 22, 2023, allowed for the sale of a maximum of 22,362 shares, and the filing states she did not sell any shares under it. The purchases will be reported separately on Forms 4. The filing is an Item 8.01 (Other Events) disclosure and contains no financial results, guidance, or operational updates. It refers to the Company's Annual Report on Form 10-K filed February 19, 2025, for risks relating to the Company, and includes standard forward-looking statement language.
Charles River Laboratories International 8-K Report, Financial Results (Feb 19, 2025)
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter 2024 revenue of $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023, with organic revenue down 1.8%. The company recorded a non-cash goodwill impairment of $215.0 million in the quarter related to its Biologics Solutions reporting unit, producing a GAAP net loss available to common shareholders of $(215.7) million, or $(4.22) per share. On a non-GAAP basis, fourth-quarter diluted earnings per share rose 8.1% to $2.66 from $2.46, driven by higher operating income and favorable below-the-line items. For full-year 2024, revenue decreased 1.9% to $4.05 billion from $4.13 billion, with organic revenue down 2.8%. GAAP diluted EPS was $0.20, down from $9.22 in 2023, while non-GAAP diluted EPS was $10.32, down 3.3% from $10.67. Segment results were mixed: Research Models and Services and Manufacturing Solutions grew full-year revenue, while Discovery and Safety Assessment revenue declined 6.3%. For 2025, management guides reported revenue growth of (7.0)% to (4.5)% and GAAP EPS of $4.30 to $4.80, with non-GAAP EPS of $9.10 to $9.60. The company expects DSA pricing to be a headwind throughout 2025, lower commercial CDMO revenue to weigh on Manufacturing growth, and plans to repurchase approximately $350 million of common stock in 2025.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Jan 14, 2025)
Charles River Laboratories International, Inc. furnished this Form 8-K under Item 7.01 (Regulation FD) ahead of a presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at approximately 5:15 p.m. Eastern time. The company posted a slide presentation that offers a preliminary assessment of its 2025 outlook. It expects 2025 revenue to decline organically in a similar range to its estimated 2024 decline, with constrained spending from global biopharma clients due to restructuring programs and pipeline reprioritization. It expects non-GAAP operating margin to be modestly below the estimated 2024 level, as cost savings can protect margin but cannot fully offset lower revenue. Full 2025 guidance is planned for release with fourth-quarter 2024 results in mid-February 2025. In its Discovery and Safety Assessment (DSA) segment, biotech demand key performance indicators stabilized in 2024 and gradually improved year over year. Global biopharma demand stabilized in the second half of 2024 after meaningful deterioration during the second quarter, and the company expects current trends to persist into 2025 and continue to pressure year-over-year growth rates. DSA pricing is expected to be a revenue headwind in 2025. The filing flags material pressure in the contract development and manufacturing organization (CDMO) business. A cell therapy client has reevaluated its manufacturing network and notified the company that it will terminate its commercial agreement, and the company expects lower commercial revenue from another cell therapy client. The company states that it is currently assessing the recoverability of goodwill and long-lived assets for a potential impairment.
Charles River Laboratories International 8-K Report, Financial Obligation (Dec 13, 2024)
On December 13, 2024, Charles River Laboratories International, Inc. ("Charles River") entered into its Tenth Amended and Restated Credit Agreement with certain financial institutions and JPMorgan Chase Bank, N.A., as administrative agent. The amendment extends the maturity date for the facilities, reduces aggregate revolving commitments from $3 billion to $2 billion, adds Charles River Laboratories, Inc. ("CRL"), a direct subsidiary, as a borrower, and makes other changes to covenants and terms. The revolving facility provides up to approximately $2 billion, is available in U.S. dollars to Charles River and CRL and in euros and sterling to certain subsidiaries in the United Kingdom, the Netherlands and Luxembourg, and matures on December 13, 2029, with no scheduled payments required before that date. Borrowings bear interest at base rate, Term SOFR, EURIBOR or daily simple RFR rates, plus a margin based on Charles River's leverage ratio. Obligations are guaranteed by CRL and secured by substantially all assets of Charles River, CRL and future material domestic subsidiaries, including a pledge of 100% of the capital stock of CRL and future material domestic subsidiaries and 65% of the capital stock of certain first-tier material foreign subsidiaries. The agreement requires compliance with an interest coverage ratio test and a leverage ratio test and includes negative covenants limiting additional indebtedness, liens, investments, mergers and acquisitions, asset sales, subsidiary distribution restrictions, affiliate transactions and changes to the business. The full agreement is filed as Exhibit 10.1 and incorporated by reference.
Charles River Laboratories International 8-K Report, Financial Results (Nov 6, 2024)
Charles River Laboratories International, Inc. reported third-quarter 2024 results for the quarter ended September 28, 2024. Revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion a year earlier, or a 2.7% decline on an organic basis. GAAP diluted earnings per share were $1.33, compared with $1.69 in the third quarter of 2023, while non-GAAP diluted earnings per share were $2.59, compared with $2.72. The GAAP operating margin fell to 11.6% from 14.8%, mainly due to restructuring costs, and the non-GAAP operating margin declined to 19.9% from 20.5%, as improvements in all three segments were offset by higher unallocated corporate costs. Segment results were mixed. Research Models and Services revenue rose 5.9% to $197.8 million, aided by the Noveprim acquisition, and Manufacturing Solutions revenue rose 12.0% to $196.9 million, with organic growth of 11.8%. Discovery and Safety Assessment revenue fell 7.4% to $615.1 million, driven by lower volume in both Discovery Services and Safety Assessment. Management said demand indicators were relatively stable in the quarter and that biotech funding had improved in 2024, though clients are still reducing spending during restructuring and pipeline reprioritization. The company narrowed and slightly raised its non-GAAP EPS guidance to $10.10 to $10.30 and lowered its GAAP EPS guidance to $5.30 to $5.50. Reported revenue growth guidance is now (3.0)% to (2.0)%. The company also authorized a new $1.0 billion stock repurchase program in August 2024, repurchased $100.7 million of shares in the third quarter, and had $899.3 million remaining under that authorization as of September 28, 2024.
Charles River Laboratories International 8-K Report, Financial Results (Aug 7, 2024)
Charles River Laboratories International, Inc. (NYSE: CRL) reported second-quarter 2024 results on August 7, 2024 (quarter ended June 29, 2024). Revenue was $1.03 billion, down 3.2% from $1.06 billion a year earlier, with organic revenue also declining 3.2%. GAAP diluted EPS was $1.74, down 7.9% from $1.89, while non-GAAP diluted EPS rose 4.1% to $2.80 from $2.69, driven mainly by lower performance-based compensation accruals and higher Manufacturing Solutions revenue and operating income. The Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments both declined on an organic basis, at 5.0% and 3.9% respectively, while Manufacturing Solutions grew 3.7% organically. The company materially cut its 2024 outlook. Reported revenue growth guidance is now (4.5)% to (2.5)%, down from 1.0% to 4.0%, and organic growth is now (5.0)% to (3.0)%, versus 0.0% to 3.0% previously. GAAP EPS guidance fell to $5.65–$5.95 from $7.60–$8.10, and non-GAAP EPS guidance fell to $9.90–$10.20 from $10.90–$11.40. Management attributed the revision to a lack of demand recovery from small and mid-sized biotech clients and softer trends from global biopharmaceutical clients, and said it no longer expects demand to improve in the second half of 2024. To address this, the Board approved a new $1.0 billion stock repurchase authorization, replacing a prior $1.3 billion program that had $129.1 million remaining when terminated. Restructuring initiatives are expected to yield annualized cost savings of over $150 million (including actions taken since last year through Q3 2024), with approximately $100 million realized in 2024.
Charles River Laboratories International 8-K Report, Shareholder Vote Results (May 10, 2024)
Charles River Laboratories International, Inc. held its Annual Meeting of Shareholders on May 8, 2024, and this Current Report on Item 5.07 reports the voting results. Shareholders elected all eleven director nominees to serve until the 2025 Annual Meeting. Shareholders also approved, on an advisory, non-binding basis, the compensation of the named executive officers, with 43,833,503 votes for, 2,299,362 against, 55,335 abstaining and 2,038,517 broker non-votes. Shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal 2024, with 45,612,837 votes for and 2,586,704 against. Shareholders did not approve the shareholder proposal submitted by PETA to publish a report on non-human primates imported by the Company, which received 11,428,432 votes for and 34,538,572 against. The filing states that the proposals are described in the Company's proxy statement dated March 29, 2024, and that Computershare Trust Company, N.A. served as independent proxy tabulator and Inspector of Election.
Charles River Laboratories International 8-K Report, Financial Results (May 9, 2024)
Charles River Laboratories International, Inc. filed a Current Report on Form 8-K on May 9, 2024, under Item 2.02 (Results of Operations and Financial Condition) to report its financial results for the first quarter ended March 30, 2024. The results are presented in a press release dated May 9, 2024, filed as Exhibit 99.1. Under Item 2.02, the information is furnished rather than filed, so it is not subject to Section 18 of the Exchange Act and is not incorporated by reference into Securities Act or Exchange Act filings unless expressly referenced. The press release contains forward-looking statements covered by the safe harbor language of the Private Securities Litigation Reform Act of 1995. The company states that the risks relating to those statements are set forth in its filings with the Securities and Exchange Commission. Investors should review those filings alongside the press release to understand the risk factors that could cause actual results to differ from the forward-looking statements. The filing also includes Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.
Charles River Laboratories International 8-K Report, Financial Results (Feb 14, 2024)
Charles River Laboratories International, Inc. reported fourth-quarter and full-year 2023 results and provided 2024 guidance in a press release furnished under Item 2.02. Fourth-quarter revenue was $1.01 billion, versus $1.10 billion in the fourth quarter of 2022, and the filing states organic revenue decreased 3.5%. Fourth-quarter GAAP diluted EPS was $3.62 and non-GAAP diluted EPS was $2.46, with GAAP EPS boosted by a $2.04 per share gain on venture capital and strategic investments, including the Noveprim Group investment. For full-year 2023, revenue rose 3.9% to $4.13 billion, organic revenue grew 6.5%, GAAP diluted EPS was $9.22, and non-GAAP diluted EPS was $10.67. Management described the 2024 demand environment as cautious and said it believes the current market environment is transitory, expecting constrained client spending to persist in 2024 but stabilizing over the year. The company guided 2024 reported revenue growth of 1.0% to 4.0%, organic growth of 0.0% to 3.0%, GAAP EPS of $7.90 to $8.40, and non-GAAP EPS of $10.90 to $11.40. The outlook assumes Noveprim contributes at least $0.30 to non-GAAP EPS. The filing also details the November 30, 2023 acquisition of an additional 41% stake in Noveprim Group, bringing its controlling interest to 90%, for $144.6 million plus up to $55.0 million in contingent payments and $12.0 million in deferred payments. Segment results were mixed: Discovery and Safety Assessment organic revenue fell 6.0% in the fourth quarter on a Discovery Services decline, while Manufacturing organic revenue grew 2.3%.
Charles River Laboratories International 8-K Report, Executive Changes (Jan 24, 2024)
Charles River Laboratories International, Inc. filed this Form 8-K under Item 5.02 to report a board change. Effective January 22, 2024, the Board increased its size from eleven to twelve members and then filled the new vacancy by appointing Ms. Reshema Kemps-Polanco as a director. The filing states she has been appointed to the existing Compensation Committee and Strategic Planning and Capital Allocation Committee. The filing states there are no arrangements or understandings under which she was selected as a director, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K. She will participate in the non-employee director compensation program. Under that program, the annual equity award before pro-rata adjustment is valued at $255,500, split 50% restricted stock units and 50% stock options, issued on the first day of the month following her appointment. New directors appointed after the Annual Meeting also receive an initial equity award and cash retainer on a pro-rata basis. Ms. Kemps-Polanco has 25 years of pharmaceutical industry experience and is currently Executive Vice President and Chief Commercial Officer of Novartis US. Her prior roles include several leadership positions at Johnson & Johnson from 2014 to 2021, and she began her career at Novartis in sales. For investors, the filing is primarily a governance update with a new independent director and no financial results disclosed.
Charles River Laboratories International 8-K Report, Executive Changes (Jan 16, 2024)
Charles River Laboratories International, Inc. (CRL) filed this Current Report under Item 5.02, which covers departures and appointments of certain officers. The Company announced on January 9 that William D. Barbo, Corporate Executive Vice President and Chief Commercial Officer, will retire at the end of 2024 after a 42-year career with the Company. Until then, he will continue as Executive Vice President and strategic advisor to ensure a smooth transition of his responsibilities. In connection with the planned retirement, Kristen Eisenhauer is assuming the role of Senior Vice President, Chief Commercial Officer. Ms. Eisenhauer has been with the Company for 20 years and has held leadership roles spanning operations management, client services, sales, and marketing. Most recently, she served as Corporate Senior Vice President, Safety Assessment Customer Excellence. For investors, the filing is a planned leadership succession in the commercial function. It discloses no financial results, guidance, or compensation terms for either executive.
Charles River Laboratories International 8-K Report, Corporate Update (Nov 15, 2023)
Charles River Laboratories International, Inc. filed this Form 8-K on November 15, 2023 under Item 8.01 (Other Events) to disclose two related actions by Chair, President and Chief Executive Officer James C. Foster. On November 14, 2023, Mr. Foster purchased 5,620 shares of the Company's common stock at an average price of $178.05, for an aggregate purchase price of approximately $1.0 million, in open market transactions. He described the purchases as reflecting his confidence in the Company's strategic direction and long-term growth prospects. His purchases will be reported separately on a Form 4. On the same day, Mr. Foster terminated his Rule 10b5-1 Trading Plan dated February 24, 2023, which had allowed for the sale of up to 112,341 shares under a pre-established formula. The filing states he terminated the plan to facilitate the purchases without unintentionally violating the short-swing profit rules of Section 16 of the Securities Exchange Act of 1934, which would have been triggered by open market sales within six months of open market purchases. The filing states that Mr. Foster did not sell any shares under the Plan. The filing is primarily an insider-activity disclosure and contains no financial results or operating metrics. It includes standard forward-looking statement safe-harbor language and references the Company's Annual Report on Form 10-K filed February 16, 2022.
Charles River Laboratories International 8-K Report, Financial Results (Nov 8, 2023)
Charles River Laboratories International, Inc. (NYSE: CRL) reported third-quarter 2023 results on November 8, 2023. Total revenue was $1.03 billion, up 3.8% from $989.2 million in the third quarter of 2022, with organic revenue growth of 4.1%. GAAP net income attributable to common shareholders was $87.4 million, down 9.4% year over year, and GAAP diluted EPS was $1.69, down 10.1% from $1.88. Non-GAAP net income rose 4.2% to $140.5 million and non-GAAP diluted EPS rose 3.4% to $2.72. The company attributed the GAAP decline mainly to site consolidation and associated costs, a loss on certain venture capital and other strategic investments, higher interest expense, and a higher tax rate. Management said third-quarter results exceeded its expectations and that early signs of more favorable demand trends were emerging, including a sequential improvement in the Safety Assessment cancellation rate. However, client spending patterns continued to pressure the Research Models and Services (RMS) segment and the Microbial Solutions business. The company said it is aligning its cost structure with the current pace of demand. Charles River updated its 2023 guidance, narrowing revenue growth and non-GAAP EPS ranges. Reported revenue growth guidance is now 2.5% to 3.5% (previously 2.5% to 4.5%), and non-GAAP EPS guidance is $10.50 to $10.70 (previously $10.30 to $10.90). GAAP EPS guidance was lowered to $7.30 to $7.50 from $7.60 to $8.20. The company described the changes as reflecting a shift in the timing of results in the second half of the year.
Charles River Laboratories International 8-K Report, Financial Results (Aug 9, 2023)
Charles River Laboratories International, Inc. (NYSE: CRL) reported second-quarter 2023 results for the quarter ended July 1, 2023, as disclosed in Exhibit 99.1, a press release dated August 9, 2023. Revenue was $1.06 billion, up 8.9% from $973.1 million a year earlier, with organic revenue growth of 11.2% driven primarily by the Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments. The Avian Vaccine divestiture reduced reported growth by 2.3%. GAAP net income attributable to common shareholders was $97.0 million, or $1.89 diluted EPS, down 11.3% from $2.13, while non-GAAP net income was $138.3 million, or $2.69 diluted EPS, down 2.9% from $2.77. The company attributed the lower earnings mainly to non-operating items, including higher interest expense and a higher tax rate, as well as the Avian divestiture. The company narrowed its 2023 guidance to the upper ends of prior ranges, now projecting reported revenue growth of 2.5% to 4.5% and non-GAAP EPS of $10.30 to $10.90 (previously $9.90 to $10.90) and GAAP EPS of $7.60 to $8.20. Management cited solid first-half performance and mitigation of NHP supply constraints, partly offset by near-term demand trends as biopharmaceutical clients reprioritize pipelines and tighten R&D budgets. Segment results were mixed: DSA revenue rose 12.1% to $663.5 million with a GAAP operating margin of 24.3%, while Manufacturing Solutions revenue fell 4.2% to $186.5 million and its GAAP operating margin dropped to 13.1% from 32.1%. The filing also notes that interest expense rose to $35.0 million in the quarter from $3.7 million a year earlier, and that the company is hosting a virtual Meeting with Management on September 21, 2023. Forward-looking statements, including risks tied to NHP supply and U.S. Department of Justice investigations into the Cambodia NHP supply chain, are described in the company's Form 10-K filed February 22, 2023.
Charles River Laboratories International 8-K Report, Shareholder Vote Results (May 15, 2023)
Charles River Laboratories International, Inc. filed this Item 5.07 report to disclose the results of its Annual Meeting of Shareholders, held on May 9, 2023. Shareholders elected all eleven director nominees to serve until the 2024 Annual Meeting. Martin W. Mackay drew the most opposition, with 28,520,093 votes for and 17,471,571 against, and Deborah T. Kochevar also received 6,572,677 votes against. The filing refers to a proxy statement dated March 30, 2023 for further detail on the proposals. Shareholders approved, on an advisory basis, the compensation of the named executive officers, with 40,252,161 votes for and 5,727,678 against. On the frequency of future say-on-pay votes, a majority favored an annual vote: 45,471,178 shares voted for one year, compared with 10,778 for two years and 515,767 for three years. The board said it currently intends to hold the advisory compensation vote every year until the next required frequency vote. Shareholders also ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2023, with 45,515,845 votes for and 2,419,202 against. Shareholders did not approve a shareholder proposal submitted by PETA asking the company to publish a report on non-human primates it imports. The proposal received 16,382,651 votes for and 29,395,105 against, with 233,421 abstentions and 1,946,418 broker non-votes. Computershare Trust Company, N.A., the company's transfer agent, served as independent proxy tabulator and Inspector of Election.
Charles River Laboratories International 8-K Report, Financial Results (May 11, 2023)
Charles River Laboratories International, Inc. reported first-quarter 2023 results in a press release (Exhibit 99.1) furnished under Item 2.02. Total revenue was $1.03 billion, up 12.6% from $913.9 million a year earlier, with organic revenue growth of 15.4% driven by the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. GAAP diluted earnings per share were $2.01, up 11.0% from $1.81, and non-GAAP diluted EPS were $2.78, up 1.1% from $2.75. The company attributed the GAAP and non-GAAP earnings increases primarily to higher revenue and operating income, partially offset by higher interest expense, a higher tax rate and the Avian Vaccine divestiture. Segment results were mixed. DSA revenue rose 21.7% to $662.4 million, with GAAP operating margin improving to 25.9% from 19.3%, supported by higher Safety Assessment study volume and price increases. RMS revenue grew 13.2% to $199.8 million, but its GAAP operating margin fell to 20.2% from 27.1%, which the company attributed mainly to the timing of large model shipments in China. Manufacturing Solutions revenue declined 13.4% to $167.3 million, and its GAAP operating margin dropped sharply to 1.3% from 24.0%, reflecting lower margins in the CDMO and Biologics Testing Solutions businesses. The company narrowed its 2023 guidance: reported revenue growth is now expected at 2.0% to 4.5% (previously 1.5% to 4.5%), organic revenue growth at 5.0% to 7.5% (previously 4.5% to 7.5%), GAAP EPS at $7.45 to $8.45, and non-GAAP EPS at $9.90 to $10.90. Management noted that Cambodian NHP supply constraints are expected to affect results principally in the second half of the year, and that demand trends are normalizing toward pre-pandemic levels.
Charles River Laboratories International 8-K Report, Financial Results (Feb 22, 2023)
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter 2022 revenue of $1.10 billion, up 21.5% from $905.1 million a year earlier, and full-year 2022 revenue of $3.98 billion, up 12.3% from $3.54 billion. Fourth-quarter GAAP diluted EPS was $3.65 and non-GAAP diluted EPS was $2.98; full-year GAAP diluted EPS was $9.48 and non-GAAP diluted EPS was $11.12. Organic revenue growth was 18.8% in the quarter and 13.4% for the year. The GAAP quarterly results were primarily driven by a gain on the sale of the Avian Vaccine business. The company also noted that the 53rd week added to 2022 contributed approximately 5.8% to fourth-quarter reported revenue growth. The filing discloses that on February 17, 2023, the company received a U.S. Department of Justice subpoena relating to an investigation into the Cambodian non-human primate (NHP) supply chain, specifically several shipments received from its Cambodian supplier. Charles River intends to fully cooperate and has voluntarily suspended NHP shipments from Cambodia. For 2023, management expects NHP supply constraints to reduce consolidated revenue growth by approximately 200 to 400 basis points, pressuring the DSA segment, while Manufacturing growth is expected to rise as CDMO actions gain traction. The company guided 2023 reported revenue growth of 1.5% to 4.5%, organic growth of 4.5% to 7.5%, GAAP EPS of $7.40 to $8.60, and non-GAAP EPS of $9.70 to $10.90. The filing is a Form 8-K furnishing the earnings press release as Exhibit 99.1. The GAAP EPS guidance excludes third-party legal and other costs related to the DOJ investigation because they are impractical to estimate at this time, and certain of these costs are expected to be excluded from non-GAAP results.
Charles River Laboratories International 8-K Report, Executive Changes (Dec 6, 2022)
Charles River Laboratories International, Inc. filed this Current Report on Form 8-K under Item 5.02, which covers director changes and compensatory arrangements. Effective December 5, 2022, the Board of Directors increased its size from ten to eleven members and filled the new vacancy by appointing Dr. Craig B. Thompson as a director. Dr. Thompson was appointed to the existing Science and Technology Committee and Strategic Planning and Capital Allocation Committee. The filing states there are no arrangements or understandings under which he was selected as a director, and no transactions requiring disclosure under Item 404(a) of Regulation S-K. He will participate in the company's non-employee director compensation program. Under that program as currently in effect, new directors appointed after the Annual Meeting receive a pro-rata initial equity award and cash retainer. The annual equity award, before pro-rata adjustment, has a value of $255,500, split 50% restricted stock units and 50% stock options, issued on the first day of the month following appointment. The filing describes Dr. Thompson's background. He served as President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center from 2010 until his retirement in September 2022, and continues to oversee a research laboratory at the Sloan Kettering Institute. He currently serves on the board of Regeneron Pharmaceuticals, Inc. and previously served on the board of Merck & Co. Inc. from 2009 to 2018.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Nov 30, 2022)
Charles River Laboratories International, Inc. filed this Form 8-K under Item 7.01 (Regulation FD Disclosure) to furnish information for its virtual presentation at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022, at approximately 9:40 a.m. ET. The filing states that management intended to address non-human primate (NHP) supply following a November 16, 2022 U.S. Department of Justice announcement that a Cambodian NHP supplier and two Cambodian officials had been criminally charged in connection with illegally importing NHPs into the United States. The company stated that it was not named or referenced in the DOJ proceedings and that it has no direct supply contracts with the indicted Cambodian supplier. Charles River said it has global supply sources, including other sources in Cambodia, which it describes as the primary country of origin of NHP imports to the United States and to the company. However, given the indictment and subsequent statements by the Cambodian government, the company is operating under the expectation that Cambodia-sourced NHPs will be difficult to obtain in the United States for some period of time. Charles River stated it is diligently working to mitigate any Cambodia NHP supply impact through ongoing efforts to procure NHPs under different supply arrangements and from other global sources. The filing includes forward-looking statement cautions, citing risks including the COVID-19 pandemic and changes in business, political, or economic conditions due to the DOJ proceedings, and references the risk factor in its Form 10-K filed February 16, 2022 on dependence on limited sources of supply.
Charles River Laboratories International 8-K Report, Financial Results (Nov 2, 2022)
Charles River Laboratories International, Inc. (NYSE: CRL) reported third-quarter 2022 results for the quarter ended September 24, 2022. Revenue was $989.2 million, up 10.4% from $895.9 million a year earlier, with organic revenue growth of 15.3% led by the Discovery and Safety Assessment (DSA) segment, where revenue rose 16.5% to $619.5 million and organic growth was 20.8%. GAAP diluted EPS was $1.88, down 6.5% from $2.01, while non-GAAP diluted EPS was $2.63, down 2.6% from $2.70. The decline in earnings was attributed mainly to lower operating margins, higher interest expense and a higher tax rate, partly offset by revenue growth. The company also announced a definitive agreement to divest its Avian Vaccine business for approximately $170 million in cash, with potential contingent payments of up to an additional $30 million. The business, part of the Manufacturing Solutions segment, is expected to close by year-end and is expected to reduce 2023 annual revenue by about $80 million and non-GAAP EPS by about $0.35. Management narrowed 2022 guidance: reported revenue growth is now 10.0% to 11.0% (previously 9.0% to 11.0%), and non-GAAP EPS is $10.80 to $10.95 (previously $10.70 to $10.95). GAAP EPS guidance is $7.90 to $8.05, narrowed to the low end of the prior range, largely due to contingent consideration adjustments related to the CDMO Sweden divestiture. The filing notes that foreign exchange remains a meaningful headwind, expected to reduce GAAP and non-GAAP EPS by $0.43 in 2022, and that 2022 includes a 53rd week that adds about 1.5% to full-year reported revenue growth.
Charles River Laboratories International 8-K Report, Financial Results (Aug 3, 2022)
Charles River Laboratories International, Inc. (NYSE: CRL) reported second-quarter 2022 results for the quarter ended June 25, 2022, in a press release furnished as Exhibit 99.1 under Item 2.02. Total revenue was $973.1 million, up 6.4% from $914.6 million in the second quarter of 2021, with organic revenue growth of 9.5%. GAAP net income attributable to common shareholders was $109.3 million and GAAP diluted EPS was $2.13, up 23.8% from $1.72. Non-GAAP diluted EPS was $2.77, up 6.1% from $2.61. Segment results were mixed: the DSA segment grew revenue 9.6% to $591.9 million with organic growth of 12.9%, while RMS revenue rose 5.5% to $186.4 million and Manufacturing Solutions revenue fell 1.5% to $194.8 million, with the CDMO business cited as a drag. The company reduced its 2022 guidance. Reported revenue growth guidance moved to 9.0%–11.0% from 13.5%–15.5%, and organic revenue growth guidance moved to 10.0%–12.0% from 12.5%–14.5%. GAAP EPS guidance was lowered to $7.90–$8.15 from $8.70–$8.95, and non-GAAP EPS guidance to $10.70–$10.95 from $11.50–$11.75. Management attributed the cut primarily to CDMO headwinds, a stronger U.S. dollar, and higher interest expense amid rising interest rates. Free cash flow guidance was lowered to approximately $360 million from approximately $450 million. The filing also includes condensed consolidated income statement, balance sheet, cash flow, and non-GAAP reconciliation schedules. For the six months ended June 25, 2022, total revenue was $1,887.1 million and net income attributable to common shareholders was $202.3 million. Interest expense for the quarter fell to $3.7 million from $16.2 million a year earlier, and other expense, net, was $39.8 million. Long-term debt, net and finance leases rose to $2.997 billion at June 25, 2022, from $2.664 billion at December 25, 2021.
Charles River Laboratories International 8-K Report, Regulation FD Disclosure (Jun 8, 2022)
Charles River Laboratories International, Inc. filed this Form 8-K under Item 7.01 (Regulation FD Disclosure) on June 8, 2022, to preview a presentation at the William Blair 42nd Annual Growth Stock Conference in Chicago on June 9, 2022. Management will post a slide presentation to its Investor Relations website that includes an updated preliminary assessment of second-quarter 2022 guidance. The filing states that the company now expects second-quarter reported revenue growth of high-single-digits year over year, compared with its prior low-double-digit outlook. Organic revenue growth expectations are unchanged at low-double-digits, and non-GAAP EPS growth is now expected to be low- to mid-single-digits, down from mid- to high-single-digits. The company attributes the reduced reported revenue and non-GAAP EPS outlook primarily to unfavorable foreign exchange movements and to a Manufacturing revenue growth rate expected to be below the first-quarter 2022 level, principally driven by the CDMO business. Charles River continues to expect DSA and RMS organic growth rates to accelerate from the first-quarter 2022 level, and states that DSA business trends remain in line with its growth expectations for the year. The company expects full-year 2022 organic revenue growth and non-GAAP EPS to remain within the guidance ranges it provided in May. The filing is a notice of a presentation and the company's guidance commentary. It includes standard forward-looking statement cautions, citing risks such as the COVID-19 pandemic, integration of acquired businesses including Explora BioLabs, client demand, foreign currency fluctuations, and the conflict between Russia and Ukraine.
Charles River Laboratories International 8-K Report, Shareholder Vote Results (May 12, 2022)
Charles River Laboratories International, Inc. filed this Current Report under Item 5.07 to report the results of its Annual Meeting of Shareholders, held on May 10, 2022. The filing states that the company's proxy statement, dated March 30, 2022, contains further information on the proposals. Shareholders elected all ten director nominees to serve until the 2023 Annual Meeting. Each nominee received more votes for than against, though the level of support varied, with Martin W. Mackay receiving 36,951,004 votes for and 8,029,626 against. Shareholders also approved, on an advisory and non-binding basis, the compensation of the named executive officers, with 39,792,720 votes for, 5,179,352 against, 24,446 abstaining and 2,058,945 broker non-votes. In addition, shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal 2022, with 44,673,788 votes for, 2,366,772 against and 14,903 abstaining. Computershare Trust Company, N.A. acted as independent proxy tabulator and Inspector of Election.
Charles River Laboratories International 8-K Report, Financial Results (May 4, 2022)
Charles River Laboratories International, Inc. reported first-quarter 2022 results for the quarter ended March 26, 2022, per a press release attached as Exhibit 99.1. Total revenue was $913.9 million, up 10.8% from $824.6 million a year earlier, with organic revenue growth of 9.4%. Acquisitions contributed 4.7% to growth, the divestiture of RMS Japan reduced reported growth by 1.6%, and foreign currency reduced it by 1.7%. GAAP net income attributable to common shareholders was $93.0 million, or $1.81 per diluted share, compared with $1.20 a year earlier. Non-GAAP diluted EPS was $2.75, compared with $2.53. By segment, Discovery and Safety Assessment revenue rose 8.6% to $544.3 million, Research Models and Services was essentially flat at $176.5 million, and Manufacturing Solutions revenue increased 31.8% to $193.1 million, driven largely by the Cognate and Vigene acquisitions. Management cited record booking activity and robust backlog growth in the DSA segment and said studies are booked well into 2023. Management expects revenue growth to accelerate from the first-quarter level. For 2022, reported revenue growth guidance was raised to 13.5% to 15.5% from 13.0% to 15.0%, reflecting the Explora BioLabs acquisition completed April 5, 2022. Organic growth guidance of 12.5% to 14.5% and non-GAAP EPS guidance of $11.50 to $11.75 were unchanged. GAAP EPS guidance was lowered to $8.70 to $8.95 from $9.20 to $9.45, reflecting acquisition-related amortization and first-quarter venture capital losses.
Charles River Laboratories International 8-K Report, Executive Changes (Mar 28, 2022)
Charles River Laboratories International, Inc. announced on March 28, 2022 that Flavia H. Pease has been appointed as its Corporate Vice President and Chief Financial Officer. She will join the company as Corporate Executive Vice President on April 25, 2022 and is expected to assume the CFO role after the filing of the Company's Form 10-Q in early May 2022. This follows the previously announced retirement of David R. Smith, who will step down as CFO once Ms. Pease takes over. Mr. Smith will then become Senior Financial Advisor and remain with the Company until February 2023. Ms. Pease, 49, has more than 20 years of financial leadership experience at Johnson & Johnson. Most recently she served as Vice President and Group Chief Financial Officer of its global Medical Devices business, which had annual revenue of $27 billion in 2021. Earlier roles included Vice President, Finance for Janssen North America and several finance positions within Johnson & Johnson. She holds a Bachelor's degree in Economics from the Pontifícia Universidade Católica in Rio de Janeiro and an MBA from Santa Clara University. The at-will offer letter sets a base salary of $600,000 and a 2022 target bonus of 70% of base salary, pro-rated to her hire date. It also provides a 2022 equity award with a grant value of $2,000,000, a one-time new hire equity award with a grant value of $1,700,000, and a one-time signing bonus of $800,000, of which $200,000 is payable within 30 days of her start date and $600,000 after 12 months of employment. The offer letter will be filed as an exhibit to the Company's Form 10-Q for the first quarter of 2022.
Charles River Laboratories International 8-K Report, Financial Results (Feb 16, 2022)
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter and full-year 2021 results in a press release furnished under Item 2.02 with this filing. Fourth-quarter revenue was $905.1 million, up 14.4% from $791.0 million a year earlier, with organic revenue growth of 10.5%. Fourth-quarter GAAP diluted EPS was $2.67 and non-GAAP diluted EPS was $2.49. For full-year 2021, revenue rose 21.1% to $3.54 billion, GAAP diluted EPS was $7.60, and non-GAAP diluted EPS was $10.32. Full-year organic revenue growth was 15.1%. By segment, Manufacturing Solutions was the fastest-growing unit in the quarter, with revenue of $205.3 million, up 47.4%, aided by the Cognate BioServices and Vigene Biosciences acquisitions. Discovery and Safety Assessment revenue was $534.1 million, up 7.9%, and Research Models and Services revenue was $165.6 million, up 5.7%, after the divestiture of RMS Japan in October 2021. Fourth-quarter GAAP results were affected by a loss from venture capital and strategic investments of $0.19 per share. The company reaffirmed its 2022 guidance: reported revenue growth of 13.0% to 15.0%, GAAP EPS of $9.20 to $9.45, non-GAAP EPS of $11.50 to $11.75, and free cash flow of about $450 million. Management expects low-teens revenue growth in 2022, supported by continued client demand and price increases.
Charles River Laboratories International 8-K Report, Executive Changes (Jan 11, 2022)
On January 11, 2022, Charles River Laboratories International, Inc. (the "Company") disclosed that David R. Smith, Corporate Executive Vice President and Chief Financial Officer, will retire. He will remain in his current position until a successor is named and the transition is completed, which is expected before the end of 2022. The Company is commencing a global search for its next CFO. Smith joined the Company in 2014 through the Discovery Services acquisition of Argenta and BioFocus and was promoted to his current role in 2015. Under Item 7.01, the Company furnished a slide presentation for the 40th Annual J.P. Morgan Healthcare Conference, to be presented January 11, 2022. The presentation describes the Company's preliminary assessment of its 2022 guidance and financial outlook. Management stated the Company is in its quiet period ahead of its fourth-quarter and full-year 2021 earnings release in February 2022, and will not comment on fourth-quarter 2021 financial performance. The presentation provides 2022 guidance: reported revenue growth of 13.0%-15.0%, organic revenue growth of 12.5%-14.5%, non-GAAP EPS of $11.50-$11.75, free cash flow of about $450 million, and capital expenditures of about $360 million. GAAP EPS guidance is $9.20-$9.45, and operating cash flow is expected to be about $810 million. The presentation also reiterates 2024 targets set at the May 2021 Investor Day, including consolidated low-double-digit organic revenue growth and a non-GAAP operating margin of about 22.5%.
Charles River Laboratories International 8-K Report, Executive Changes (Dec 27, 2021)
Charles River Laboratories International, Inc. filed this Form 8-K on December 27, 2021 under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). The filing discloses that on December 22, 2021, the Compensation Committee of the Board of Directors approved a one-time, long-term equity award to Joseph W. LaPlume, Corporate Executive Vice President, Corporate Development & Strategy. The company says the award recognizes Mr. LaPlume's prior contributions to and continued critical role in the company's growth, and is intended to further incentivize him toward the achievement of the company's strategic business goals over the next five years. The effective grant date is December 25, 2021, with an intended grant date fair value of $5,000,000. Half of the award, $2.5 million on the stated intended grant date fair value basis, is issued as restricted stock units that vest on a cliff basis five years from the grant date. The other half is issued as performance share units (PSUs) based solely on five-year relative total shareholder return (rTSR) compared with the Standard & Poor's Healthcare 500 Index, with 100% payout attained upon 55% rTSR performance. The filing states the award agreements are attached as Exhibits 10.1 (restricted stock unit award) and 10.2 (performance share unit award). For investors, the filing is narrow in scope: it reports a single executive compensation grant rather than a change in leadership, financial results, or guidance. The award's five-year cliff vesting and purely relative TSR performance condition tie a substantial portion of the executive's compensation to long-term shareholder returns over the stated period.
Charles River Laboratories International 8-K Report, Bylaw Amendment (Dec 15, 2021)
Charles River Laboratories International, Inc. filed this Form 8-K on December 15, 2021 to report amendments to its Amended and Restated By-Laws. On December 13, 2021, the Board of Directors amended the By-Laws to implement proxy access, effective immediately. Under the amended By-Laws, a stockholder, or a group of up to twenty stockholders, owning at least three percent of the Company's outstanding stock continuously for at least three years may nominate and include in the Company's annual meeting proxy materials director nominees constituting up to the greater of two directors or twenty percent of the number of directors serving on the Board at the time of nomination, provided the stockholder(s) and nominee(s) satisfy the requirements in the By-Laws. The amended By-Laws also include conforming, clarifying and updating changes that supplement the proxy access by-law, along with other routine and non-substantive updates and revisions. The filing states that the description is qualified in its entirety by the full text of the Sixth Amended and Restated By-Laws, filed as Exhibit 3.1. For investors, the principal item is the adoption of proxy access, which gives qualifying long-term shareholders a defined route to place director nominees on the company's proxy ballot. The filing does not discuss any financial results, financial impact, or reasons for the change beyond the described amendments.
Charles River Laboratories International 8-K Report, Executive Changes (Nov 12, 2021)
Charles River Laboratories International, Inc. (NYSE: CRL) announced on November 11, 2021 that Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment and Biologics Testing Solutions, has been promoted to Chief Operating Officer, effective immediately. She will also add oversight of the Research Models and Services (RMS) business to her existing responsibilities and will continue to report directly to James C. Foster, Chairman, President and Chief Executive Officer. The filing states that her appointment was not made pursuant to any arrangement or understanding with any other person, and that she will receive salary, bonus and equity opportunity at levels consistent with her position and scope of responsibility. The filing describes Ms. Girshick as a three-decade veteran of the company, having joined Charles River in 1989. Her prior roles included Corporate Vice President, Biologics Testing Solutions (2010), Corporate Senior Vice President, Research Models and Biologics Testing Solutions (2013), and Corporate Executive Vice President overseeing Discovery, Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services (2018). In 2021 she also assumed responsibility for the Cell and Gene Therapy CDMO business. The press release notes she has been overseeing the integration of the Cognate BioServices and Vigene Biosciences acquisitions. The filing is primarily a management-succession disclosure and does not include financial results or guidance. The press release references Mr. Foster's May 2021 amended employment agreement, which extended his employment through February 12, 2026, and the company's forward-looking statement cautions, which refer to risk factors in its Form 10-K filed February 17, 2021 and Form 10-Q filed November 3, 2021.